FDA-cleared profile

BrightHeart View Classifier

BrightHeart · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Automatic standard-view detection and frame extraction to support acquisition and interpretation of second- or third-trimester fetal heart ultrasound.

Clinical role
Adjunct to fetal ultrasound acquisition and interpretation; it classifies standard views and is not a replacement for the interpreting clinician.
Images and patients
Ultrasound · Obstetric/Fetal
Key limitation
Keep in mind: The exact FDA validation used GE, Philips, Samsung and Siemens ultrasound devices and pregnancies at 18 weeks or later recorded with transabdominal probes; performance was lower or less certain in some small demographic subgroups.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatic standard-view detection and frame extraction to support acquisition and interpretation of second- or third-trimester fetal heart ultrasound.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Obstetric/Fetal Input: Fetal 2D ultrasound images and video clips from transabdominal examinations at 18 weeks of gestation or later.
  • Who uses it?Intended users: Qualified and trained sonographers, maternal-fetal medicine specialists, obstetricians, gynecologists and fetal surgeons.
  • What does the software produce?Output: Automatic classification of fetal cardiac standard views and automatically extracted example frames for review and documentation.
  • What is its most important limitation?Key limitation: The exact FDA validation used GE, Philips, Samsung and Siemens ultrasound devices and pregnancies at 18 weeks or later recorded with transabdominal probes; performance was lower or less certain in some small demographic subgroups.

Clinical takeaway. Clinical role: Automatic standard-view detection and frame extraction to support acquisition and interpretation of second- or third-trimester fetal heart ultrasound.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA performance set contained 2,290 clinically acquired images and video frames from 579 fetal ultrasound examinations at 8 centers; mean standard-view recognition sensitivity was 0.939 and specificity was 0.984.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatic standard-view detection and frame extraction to support acquisition and interpretation of second- or third-trimester fetal heart ultrasound.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Adjunct to fetal ultrasound acquisition and interpretation; it classifies standard views and is not a replacement for the interpreting clinician.
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Fetal 2D ultrasound images and video clips from transabdominal examinations at 18 weeks of gestation or later.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Automatic classification of fetal cardiac standard views and automatically extracted example frames for review and documentation.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Fetal anatomic ultrasound examinations in the second or third trimester using transabdominal probes.
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Qualified and trained sonographers, maternal-fetal medicine specialists, obstetricians, gynecologists and fetal surgeons.
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
The exact FDA validation used GE, Philips, Samsung and Siemens ultrasound devices and pregnancies at 18 weeks or later recorded with transabdominal probes; performance was lower or less certain in some small demographic subgroups.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
The exact FDA performance set contained 2,290 clinically acquired images and video frames from 579 fetal ultrasound examinations at 8 centers; mean standard-view recognition sensitivity was 0.939 and specificity was 0.984.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA performance set contained 2,290 clinically acquired images and video frames from 579 fetal ultrasound examinations at 8 centers; mean standard-view recognition sensitivity was 0.939 and specificity was 0.984.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
0.939 (95% CI, 0.917 ; 0.960)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
0.984 (95% CI, 0.973 ; 0.996)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Mean standard-view recognition sensitivity

0.939 proportion

  • EndpointStandard-view recognition
  • Population2,290 images and video frames from 579 fetal ultrasound examinations at 8 centers
  • Tested versionBrightHeart View Classifier release reviewed in K243684

Mean standard-view recognition specificity

0.984 proportion

  • EndpointStandard-view recognition
  • Population2,290 images and video frames from 579 fetal ultrasound examinations at 8 centers
  • Tested versionBrightHeart View Classifier release reviewed in K243684

BrightHeart View Classifier standard-view recognition validation

  • DesignRetrospective performance validation with stratified subgroup analysis
  • PopulationClinically acquired fetal ultrasound images and video frames from transabdominal examinations at 18 weeks of gestation or later
  • Scopeexact submission
  • Tested versionBrightHeart View Classifier release reviewed in K243684
  • Samplen=579
  • Sites8
  • IndependenceSponsor or vendor study

K243684 FDA 510(k) summary

The sample comprised 2,290 images and frames; the exact labeling limits use to the validated ultrasound vendors and examination conditions.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Fetal 2D ultrasound images and video clips from transabdominal examinations at 18 weeks of gestation or later.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for BrightHeart View Classifier, K243684

  2. Routing

    Source context, not route validation: The current BrightHeart family platform describes a standalone fetal-heart workflow with support for major ultrasound manufacturers, a cart-side tablet option, and results linked into reporting and a web view; exact K243684 interfaces are not established.

    Scope: Product family.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · B-Right AI Platform

  3. AI processing

    Source context, not route validation: The FDA materials describe a cloud-based, software-only workflow with qualified users reviewing fetal ultrasound images or clips.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for BrightHeart View Classifier, K243684

  4. Returned objects

    Source context, not route validation: Automatic classification of fetal cardiac standard views and automatically extracted example frames for review and documentation.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for BrightHeart View Classifier, K243684

  5. Viewer/worklist/report

    Unresolved route: Automatic classification of fetal cardiac standard views and automatically extracted example frames for review and documentation.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) decision record and summary reviewed for BrightHeart View Classifier, K243684

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA materials describe a cloud-based, software-only workflow with qualified users reviewing fetal ultrasound images or clips.
  • Exact FDA submission
  • Checked 2026-09-06
Integration
The current BrightHeart family platform describes a standalone fetal-heart workflow with support for major ultrasound manufacturers, a cart-side tablet option, and results linked into reporting and a web view; exact K243684 interfaces are not established.
  • Product family
  • Checked 2026-09-07
Security
BrightHeart's security page describes a coordinated vulnerability disclosure program: a cybersecurity team monitoring for vulnerabilities, vulnerability report submission to support@brightheart.ai in a defined format, confirmation of receipt within ten business days, investigation and risk analysis, and a findings summary returned to the reporter.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement. The page is a coordinated vulnerability disclosure program description (last updated 2025-06-19); no certification or audit report was read, and exact-release scope is not established.

Monitoring
BrightHeart's security page (last updated 2025-06-19) states a cybersecurity team monitoring for vulnerabilities and a coordinated vulnerability disclosure program with receipt confirmation within ten business days, investigation and risk analysis, and a findings summary returned to the reporter.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names BrightHeart generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Automatic view and frame workflow

The exact device classifies standard fetal cardiac views and extracts example frames for review.

exact submission · checked 2026-09-06

Family reporting integration

BrightHeart family material describes results linked into reporting and a standalone web view; exact K243684 integration details are not established.

product family · checked 2026-09-07

Supported ultrasound ecosystem

The exact validation covered GE, Philips, Samsung and Siemens devices; current family material separately describes integration with major manufacturers.

exact submission · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243684
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Obstetric/Fetal
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-05-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
25Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The stored candidate metadata contained empty PubMed and clinical-trial ID arrays; metadata was screened, not full-text or registry-reviewed. The stored recall candidate record was empty and no event was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor manual, peer reviewed publication, clinical trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-07 - Exact FDA submission

    No numeric price was published in the reviewed sources.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "BrightHeart reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. K243684 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. BrightHeart View Classifier model card (K243684)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. FDA 510(k) decision record and summary reviewed for BrightHeart View Classifier, K243684

    U.S. Food and Drug Administration - Published 2025-05-07 - Accessed 2026-09-06

    Scope: identity, intended_use, performance, limitations, implementation

  8. B-Right AI Platform

    BrightHeart - Accessed 2026-09-07

    Scope: product_family, standard_view_workflow, ultrasound_integration, reporting

  9. BrightHeart: Security (Coordinated Vulnerability Disclosure)

    BrightHeart - Accessed 2026-10-27

    Scope: security

Research history

  1. K243684 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250959

BioticsAI

Bioticsai, Inc.

Authorized purpose: BioticsAI assists healthcare professionals during and after fetal ultrasound acquisition and interpretation by detecting views and anatomical structures and facilitating quality-criteria verification on DICOM images and frames; it is a concurrent reading aid for the labeled GE ultrasound and prenatal population.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2025-12-22
FDA-cleared K261519

Sonio Suspect

Sonio

Authorized purpose: Concurrent physician reading aid for specified abnormal fetal ultrasound findings; patient management must not rely solely on the analysis.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2026-06-04
FDA-cleared K252148

Butterfly Gestational Age Tool

Butterfly Network, Inc.

Authorized purpose: Butterfly Gestational Age Tool estimates gestational age for a singleton intrauterine pregnancy presumed to be 16 to 37 weeks within the labeled Butterfly ultrasound workflow; qualified professionals must review the output.

Modality
Ultrasound
Anatomy
Obstetric/Fetal
Decision
2026-03-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history